As Horizon Pharma Plc (HZNP) Stock Value Declined, Shareholder Rhenman & Partners Asset Management Ab Has Cut Holding

May 20, 2018 - By Migdalia James

Horizon Pharma Public Limited Company (NASDAQ:HZNP) LogoInvestors sentiment increased to 1.04 in Q4 2017. Its up 0.04, from 1 in 2017Q3. It improved, as 30 investors sold HZNP shares while 53 reduced holdings. 33 funds opened positions while 53 raised stakes. 128.65 million shares or 2.76% less from 132.29 million shares in 2017Q3 were reported. Invesco owns 128,192 shares. Piedmont Ltd Liability holds 0.01% or 45,170 shares. Macquarie Grp Inc Limited invested in 0% or 12,900 shares. Credit Suisse Ag reported 165,912 shares stake. Finance Architects owns 600 shares or 0% of their US portfolio. Point72 Asset Mngmt LP owns 372,800 shares. Nomura Incorporated has invested 0% in Horizon Pharma Public Limited Company (NASDAQ:HZNP). D E Shaw reported 353,875 shares. Massachusetts Financial Com Ma owns 93,643 shares for 0% of their portfolio. Moreover, Balyasny Asset Management Lc has 0.05% invested in Horizon Pharma Public Limited Company (NASDAQ:HZNP). Us Financial Bank De accumulated 0% or 83,664 shares. Swiss Retail Bank accumulated 278,156 shares. Vanguard Grp accumulated 0.01% or 13.48M shares. Citigroup owns 558,631 shares. Tiaa Cref Investment Management Ltd Com has 501,737 shares.

Rhenman & Partners Asset Management Ab decreased its stake in Horizon Pharma Plc (HZNP) by 34.98% based on its latest 2017Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 1.05M shares as the company’s stock declined 6.58% with the market. The institutional investor held 1.95M shares of the major pharmaceuticals company at the end of 2017Q4, valued at $28.54 million, down from 3.01M at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Horizon Pharma Plc for a number of months, seems to be less bullish one the $2.49 billion market cap company. The stock increased 0.27% or $0.04 during the last trading session, reaching $15.11. About 1.55 million shares traded. Horizon Pharma Public Limited Company (NASDAQ:HZNP) has declined 6.20% since May 20, 2017 and is downtrending. It has underperformed by 17.75% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $740.07 million US Long portfolio, upped its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9,154 shares to 31,154 shares, valued at $11.71 million in 2017Q4, according to the filing. It also increased its holding in Humana Inc (NYSE:HUM) by 17,000 shares in the quarter, for a total of 58,000 shares, and has risen its stake in Sage Therapeutics Inc (NASDAQ:SAGE).

Analysts await Horizon Pharma Public Limited Company (NASDAQ:HZNP) to report earnings on August, 6. They expect $0.33 earnings per share, down 19.51 % or $0.08 from last year’s $0.41 per share. HZNP’s profit will be $54.47 million for 11.45 P/E if the $0.33 EPS becomes a reality. After $0.03 actual earnings per share reported by Horizon Pharma Public Limited Company for the previous quarter, Wall Street now forecasts 1,000.00 % EPS growth.

More notable recent Horizon Pharma Public Limited Company (NASDAQ:HZNP) news were published by: Streetinsider.com which released: “Paulson’s 13F Shows New Stake in Goldcorp (GG), Increase in Discovery (DISCA), Viacom (VIAB) (more…)” on May 15, 2018, also Nasdaq.com with their article: “Horizon Pharma plc Announces the US Patent and Trademark Office Issuance of Additional Notices of Allowance With …” published on May 08, 2018, Seekingalpha.com published: “Horizon Pharma Plc (HZNP) Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. More interesting news about Horizon Pharma Public Limited Company (NASDAQ:HZNP) were released by: Bizjournals.com and their article: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” published on May 17, 2018 as well as Nasdaq.com‘s news article titled: “Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” with publication date: May 04, 2018.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Coverage

Among 6 analysts covering Horizon Pharma Inc (NASDAQ:HZNP), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Horizon Pharma Inc had 11 analyst reports since November 30, 2017 according to SRatingsIntel. On Friday, March 2 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. On Tuesday, January 30 the stock rating was maintained by Piper Jaffray with “Buy”. As per Thursday, November 30, the company rating was maintained by UBS. As per Monday, May 7, the company rating was maintained by Mizuho. The firm has “Buy” rating given on Wednesday, April 11 by Mizuho. The firm earned “Buy” rating on Sunday, April 15 by Cantor Fitzgerald. The firm has “Buy” rating by Mizuho given on Friday, January 12. Piper Jaffray maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Wednesday, February 28. Piper Jaffray has “Buy” rating and $22.0 target. Cowen & Co maintained Horizon Pharma Public Limited Company (NASDAQ:HZNP) rating on Wednesday, February 28. Cowen & Co has “Buy” rating and $24.0 target. The company was maintained on Wednesday, February 28 by Cantor Fitzgerald.

Horizon Pharma Public Limited Company (NASDAQ:HZNP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.